Welcome to Market Watch: Healthcare, Pharma & Biotech

Pharmaceutical contract manufacturing has moved from a capacity solution to a core strategic function across global pharma.

What was once a transactional outsourcing decision is now a long-term competitive lever. As biologics, cell and gene therapies, and increasingly complex drug pipelines expand, pharmaceutical companies are relying on CDMOs to deliver scale, speed and regulatory certainty.

According to Visiongain analysis, the pharmaceutical contract manufacturing market is valued at US$171.0 billion in 2026 and is projected to reach US$367.1 billion by 2036, growing at a CAGR of 7.9%.

This week, we examine how outsourcing is being reshaped by biologics demand, supply chain realignment and technology-driven manufacturing.

Visiongain Top Takeaways

• Biologics Outsourcing Is Driving Market Expansion: Demand for monoclonal antibodies, ADCs, and cell and gene therapies is accelerating investment in specialised CDMO capacity.
• Supply Chain Resilience Is Reshaping Sourcing Strategy: Pharmaceutical companies are diversifying suppliers, nearshoring production and building redundancy into manufacturing networks.
• Advanced Therapies Are Raising Barriers to Entry: Cell and gene therapy manufacturing requires specialist expertise, creating high barriers and strong pricing power for leading CDMOs.
• Continuous Manufacturing Is Moving Into Commercial Use: Regulatory support is accelerating adoption, improving efficiency, and reducing time-to-market.
• Consolidation Is Redefining Competition: M&A and capacity expansion are concentrating capability among large, integrated CDMOs.

The Outsourcing Inflection: Pharma Manufacturing’s Structural Reset

Pharma manufacturing is undergoing a fundamental shift. Outsourcing is no longer a tactical decision. It is becoming a core part of how companies design and operate their supply chains.

Patent cliffs, manufacturing complexity and regional resilience requirements are driving this change. CDMOs are moving beyond capacity provision to become innovation partners, embedding advanced technologies, digital quality systems, serialisation and regional production hubs within global supply networks.

This marks a move from transactional outsourcing to long-term collaboration, where agility, compliance and scalability define competitive advantage.

Visiongain Insight: The shift to outsourcing is long-term, not cyclical. CDMOs that invest in advanced therapies, continuous manufacturing and digital quality infrastructure will define how medicines are produced over the next decade.

Biologics and Advanced Therapies: The Growth Engine

Biologics and advanced therapies are transforming the outsourcing landscape. With more than 7,000 molecules in development, including antibodies, ADCs and cell and gene therapies, manufacturing requirements are becoming more complex.

Viral vectors, autologous cell therapies and plasmid DNA require specialised facilities, regulatory expertise and advanced process capabilities. Capacity remains constrained, particularly in fill-finish and late-stage manufacturing, supporting premium pricing and long-term partnerships for CDMOs with established platforms.

Visiongain Insight: Biologics and advanced therapy manufacturing capacity is one of the scarcest resources in the pharmaceutical value chain. CDMOs that secured this capability early are gaining a lasting competitive advantage, while others risk being excluded from the fastest-growing pipeline segments.

Geopolitics and Supply Security: Redrawing the CDMO Map

The COVID-19 pandemic exposed the pharmaceutical industry’s reliance on concentrated API production, particularly in Asia. In response, governments and sponsors are prioritising supply security.

Policies across the US, Europe, Japan, India and the UK are encouraging domestic manufacturing, diversification and redundancy. This is driving investment into North America and Europe, while Asia continues to evolve towards higher compliance and quality standards.

Visiongain Insight: The reconfiguration of pharmaceutical supply chains reflects a fundamental repricing of manufacturing risk. CDMOs that invest in multi-region production, regulatory alignment and supply assurance capabilities will become critical partners in future procurement strategies.

Continuous Manufacturing and Digital Quality: The Technology Frontier

Pharmaceutical sponsors are no longer evaluating CDMOs solely on capacity. Continuous manufacturing, now explicitly endorsed by the FDA and EMA, delivers the process consistency and tech transfer speed that compressed development timelines demand.

Layered on top, AI-assisted analytics, real-time release and predictive batch records are redefining what quality maturity looks like. For sponsors and regulators alike, digital infrastructure has become a clear signal of a manufacturing partner that can deliver speed, consistency and compliance at scale.

Visiongain Insight: CDMOs that deploy continuous manufacturing and digital quality infrastructure together are not simply improving operational efficiency. They are repositioning their value proposition from capacity provider to technology partner. This will drive pricing power and client retention as pharmaceutical companies evaluate CDMOs on innovation capability, not just compliance.

Competitive Pressures Transforming Contract Manufacturing Models

Demand for contract manufacturing remains strong, supported by biologics growth, generic drug production and expanding demand in emerging markets.

However, competition is becoming more concentrated and more bifurcated. Large players such as Lonza, Samsung Biologics, Catalent, Thermo Fisher and WuXi are leading in biologics manufacturing, while smaller CDMOs compete on niche capabilities or regional strengths. Sub-scale providers are facing growing consolidation pressure as pharmaceutical companies prioritise integrated, end-to-end partnerships.

At the same time, consolidation is accelerating. Strategic acquisitions, capacity expansion and private equity investment are creating a smaller group of large, integrated CDMOs capable of supporting complex therapies at scale.

Visiongain Insight: Pharmaceutical companies that partner with CDMOs offering end-to-end capabilities, from development through to commercial scale, will achieve faster time to market, stronger regulatory outcomes and more resilient supply chains. The shift from transactional outsourcing to strategic partnership is now defining the market.

Market Outlook: Growth with Lasting Change

The pharmaceutical contract manufacturing market is entering a period of sustained growth, driven by expanding biologics pipelines, increasing outsourcing and rising manufacturing complexity.

However, growth will not be evenly distributed. Value is shifting towards CDMOs that can offer integrated capabilities, advanced technologies and global manufacturing reach. Over the next decade, execution capability, not demand generation, will determine market leadership.

Capacity constraints in biologics and advanced therapies are likely to persist, supporting strong demand and premium pricing for specialised providers. At the same time, continued consolidation will concentrate market share among a smaller group of large, well-capitalised CDMOs.

For pharmaceutical companies, the priority is clear. Selecting the right manufacturing partner is becoming a strategic decision that directly affects speed to market, regulatory outcomes and supply chain resilience.

Visiongain Insight: The next phase of growth in pharmaceutical contract manufacturing will be defined by execution, not access to demand. CDMOs that can scale specialised capabilities, deliver consistently across regions and integrate digital and manufacturing platforms will capture disproportionate value. Those that cannot will face growing pressure in a more concentrated and capability-driven market.

From Visiongain

Visiongain’s Pharmaceutical Contract Manufacturing Market Report 2026–2036 examines how outsourcing strategies, biologics demand, capacity expansion, regulatory pressures, and supply chain resilience are reshaping the global contract manufacturing landscape.

The report provides detailed revenue forecasts by service type, product category, end user, and key regions, alongside company intelligence on leading players, including Lonza, Catalent, Thermo Fisher Scientific, Recipharm, and Samsung Biologics.

To identify the segments, regions, and companies best positioned for growth, request sample pages.

Latest Reports

Detailed market forecasts, competitive analysis, and sector insights help R&D, manufacturing, supply chain, and commercial teams make decisions.

• Pharmaceutical Contract Manufacturing Market Report 2026-2036
• Pharmaceutical Packaging Market Report 2026-2036
• Vaccine Contract Manufacturing Market Report 2026-2036
• Decentralised Clinical Trials Market Report 2026-2036
• Anti-obesity Drugs Market Report 2026-2036
• Longevity Market Report 2026-2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com